Tequin drugmaker named in
class-action lawsuit
Gatifloxacin-induced hepatotoxicity and acute pancreatitis.
Cheung O, Chopra K, Yu T, Nalesnik MA, Amin S, Shakil AO.
Gatifloxacin-induced Purpura –
An Unusual Adverse Drug Reaction
Imrana Masood, R Bhargava, Zuber Ahmed, DK Sharma, SZ Rehman, SS
Amin: JIACM 2005; 6(3): 239-40
Dear Health Care
Professional Letter issued by Bristol-Myers Squibb (BMS) Canada,
following discussions with Health Canada, regarding the Adverse
Drug Reactions associated with the use of TEQUIN* (gatifloxacin).
December 19, 2005
Dear Health
Care Provider Letter issued by Bristol-Myers Squib, following
discussions with the FDA, Adobe Reader Required to View
FDA Label
Changes for Tequin, Adobe Reader Required to View
Bristol-Myers To Stop
Selling the Antibiotic Tequin due to Safety Risk
Bristol-Myers Squibb Hangs
No Sale Sign on Tequin
Problem-plagued antibiotic
to come off the market
Drug
Company Taking Tequin Off Market
